Inmune Bio, Inc. — Board/Management Information 2021

Jun 24, 2021

8-K 1 ea143253-8k_inmunebio.htm CURRENT REPORT

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 22, 2021

| INMUNE
BIO INC. |
| --- |
| (Exact
name of registrant as specified in charter) |

Nevada	001-38793	47-5205835
(State
or other jurisdiction	(Commission
File Number)	(IRS
Employer
of
incorporation)		Identification
No.)

1200 Prospect Street, Suite 525, La Jolla, CA 92037

(Address of Principal Executive Offices) (Zip Code)

(858) 964 3720

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title
of each class | Trading
Symbol(s) | Name
of each exchange on which registered |
| --- | --- | --- |
| Common
Stock, par value $0.001 per shares | INMB | The
NASDAQ Stock Market LLC |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As previously reported on a Current Report on Form 8-K that was filed with the Securities and Exchange Commission on June 3, 2021, on June 1, 2021, the stockholders of INmune Bio, Inc. (the “Company”) approved the Company’s 2021 Stock Incentive Plan (the “2021 Plan”), pursuant to which 2,000,000 shares of the Company’s common stock will be made available for issuance under the 2021 Plan.

On January 22, 2021, the Compensation Committee of the Board of Directors of the Company approved the issuance an option for each of the non-employee directors to purchase an aggregate of 95,125 shares of the Company’s common stock. Each non-employee director (“Optionee”) was granted an option to purchase 19,025 shares of the Company’s common stock. The options shall vest quarterly over three years and have an exercise price of $17.49 per share. The Options were granted from the 2021 Plan. The Company will execute a stock option agreement with each Optionee.

On January 22, 2021, the Compensation Committee of the Board of Directors of the Company approved the issuance of an option to Ramond J. Tesi, the Company’s Chief Executive Officer, to purchase 70,663 shares of the Company’s common stock and the issuance of an option to David Moss, the Company’s Chief Financial Officer, to purchase 70,663 shares of the common stock. The options granted to Dr. Tesi and Mr. Moss have at an exercise price of $17.49 per share and, subject to the terms of the 2021 Plan and the governing option award agreement, twenty-five percent of the option granted Dr. Tesi and Mr. Moss will vest 12 months from the Grant Date and thereafter the reaming unvested option will become vested and exercisable pro rata on a monthly basis over three (3) years (1/36 per month) until the Officer is 100% vested which shall occur on the four-year anniversary of the Grant Date. The options were granted from the 2021 Plan. The Company will execute a stock option agreement with Dr. Tesi and Mr. Moss.

The option grants referenced above are qualified by reference to the form of option agreement which is being filed as exhibit to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d)

The following exhibits are being filed herewith.

Exhibit No	Description
10.1	Form of Option Agreement between the Company and Non-Employee Directors
10.2	Form of Option Agreement for Employees of the Company

Field: Page; Sequence: 2

Field: Sequence; Type: Arabic; Name: PageNo 1 Field: /Sequence

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| /s/
David Moss |
| --- |
| David
Moss |
| Chief
Financial Officer |

2

Field: Rule-Page

Field: /Rule-Page